Axillary lymph node status is one of the key determinants of the prognosis of breast cancer patients.Its knowledge is necessary not only for staging of the disease but also to assign patients to the appropriate adjuvant treatment.Axillary lymph node dissection (ALND) is still considered the only reliable way to determine axillary lymph node status in patients treated with neoadjuvant therapy, although some authors have attempted to find a less invasive alternative to this procedure, namely ultrasound.Unfortunately, this surgical procedure is associated with severe postoperative morbidity, In early breast cancer, sentinel lymph node biopsy (SLNB) became a firmly established surrogate for standard axillary dissection with considerably lower morbidity.Reliability of this approach has been validated in many clinical studies, the majority of them attaining success rates for identification and removal of sentinel lymph node (SLN) between 95 and 100% and false negative rates between 5 and 10%.